Stratosvir join cancer patients in their fight for effective, safe, non-toxic cancer treatments that increase quality of life and survival. As a weapon, they are developing viral immunotherapy which has the potential to drastically improve the clinical treatment of solid tumours and their metastases.
Funded by Deep Science Ventures, its partners and CRUK, Stratosvir has assembled significant expertise in virology, immunology, oncology and molecular engineering to guide its mission. Their aim is for innovations to overcome the barriers to widespread use of viral immunotherapy.